News1 min read
The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus
About this article
- Published
- Further reading
- BioPharm International(opens in a new tab)
From BioPharm International — The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus
Read the original report from BioPharm International.